Repurposing of long-acting incretin-based therapies, including the GLP-1 receptor agonist semaglutide, the dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonist tirzepatide, and the triple GLP-1/GIP/glucagon agonist retatrutide, may offer a promising strategy treating AUD
(18) Government insurance programs include the following: Medicare, Medicaid, Medigap VA Veteran Administration DOD Department of Defense TRICARE Any state-specific or federal medical/pharmaceutical benefit or assistance program Self-Pay Compounded versions of Semaglutide, often offered through telehealth providers to self-pay patients, typically cost $150-$300/month
Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among U.S
Not for human consumption, medical, veterinary, clinical, diagnostic or treatment use.
For a broader comparison of side effect profiles, our three-way comparison guide covers the key differences
Nearly 10,000 Michigan members lost coverage when Blue Cross Blue Shield of Michigan dropped the drugs for fully insured large groups
